Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 291,708,608
  • Shares Outstanding, K 950,160
  • Annual Sales, $ 28,318 M
  • Annual Income, $ 5,582 M
  • 60-Month Beta 0.40
  • Price/Sales 10.27
  • Price/Cash Flow 32.22
  • Price/Book 30.39
Trade LLY with:

Options Overview Details

View History
  • Implied Volatility 30.43% ( -0.75%)
  • Historical Volatility 30.85%
  • IV Percentile 65%
  • IV Rank 54.47%
  • IV High 38.58% on 01/24/22
  • IV Low 20.69% on 06/22/21
  • Put/Call Vol Ratio 2.16
  • Today's Volume 5,891
  • Volume Avg (30-Day) 3,691
  • Put/Call OI Ratio 1.33
  • Today's Open Interest 121,883
  • Open Int (30-Day) 130,698

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate 1.89
  • Number of Estimates 4
  • High Estimate 2.12
  • Low Estimate 1.80
  • Prior Year 1.87
  • Growth Rate Est. (year over year) +1.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
280.59 +9.42%
on 04/27/22
310.42 -1.10%
on 05/25/22
+21.81 (+7.65%)
since 04/25/22
3-Month
244.59 +25.52%
on 02/28/22
314.00 -2.23%
on 04/07/22
+56.16 (+22.39%)
since 02/25/22
52-Week
195.50 +57.04%
on 05/27/21
314.00 -2.23%
on 04/07/22
+107.79 (+54.11%)
since 05/25/21

Most Recent Stories

More News
Why This FDA Approval Is a Game Changer for Eli Lilly

It could mean billions in revenue for the company.

LLY : 307.01 (+0.34%)
NVO : 105.25 (-2.53%)
ImmunoGen (IMGN) Ovarian Cancer Drug BLA Gets Priority Review

ImmunoGen (IMGN) gets priority review from the FDA for the BLA seeking approval for its lead candidate, mirvetuximab soravtansine, for treating platinum-resistant ovarian cancer.

RHHBY : 42.9900 (-0.54%)
LLY : 307.01 (+0.34%)
JAZZ : 148.01 (+3.52%)
IMGN : 3.47 (-1.98%)
Lilly's (LLY) Olumiant Gets CHMP Nod for Alopecia Areata

The CHMP gives a positive opinion and recommends approval of Lilly's (LLY) Olumiant to treat adults with severe alopecia areata.

LLY : 307.01 (+0.34%)
INCY : 76.51 (+1.86%)
AGLE : 1.5000 (+9.49%)
LPTX : 1.1900 (+6.25%)
Stocks Recover Late on Bullard Comments

What you need to know… The S&P 500 Index ($SPX ) (SPY ) on Friday closed up +0.01%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.03%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down...

$SPX : 3,978.73 (+0.95%)
SPY : 397.37 (+0.88%)
$DOWI : 32,120.28 (+0.60%)
DIA : 321.28 (+0.59%)
$IUXX : 11,943.93 (+1.48%)
QQQ : 291.26 (+1.40%)
ROST : 81.36 (+4.83%)
DG : 195.34 (-0.31%)
TJX : 61.22 (+2.58%)
DLTR : 133.59 (+2.60%)
DE : 342.97 (+1.76%)
CAT : 209.31 (+1.78%)
Radius (RDUS), Menarini Post Positive Data on Breast Cancer Drug

Radius (RDUS) and partner Menarini announce data from a late-stage study on breast cancer drug.

LLY : 307.01 (+0.34%)
AMGN : 253.01 (+0.44%)
ALKS : 28.85 (+1.76%)
RDUS : 6.00 (+1.18%)
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck, and Glaxo

Eli Lilly, Novo Nordisk, Merck, and Glaxo are part of Zacks Industry Outlook article.

GSK : 44.97 (-0.07%)
NVO : 105.25 (-2.53%)
MRK : 93.75 (-0.94%)
LLY : 307.01 (+0.34%)
Pharma Stock Roundup: FDA Nod to PFE COVID Jab for Age 5-11 & LLY's Tirzepatide

FDA grants emergency approval to Pfizer's COVID-19 vaccine for use in children 5- to 11-year old and approves Lilly's (LLY) novel diabetes treatment, Mounjaro (tirzepatide).

AZN : 66.81 (+0.24%)
PFE : 53.71 (+0.56%)
LLY : 307.01 (+0.34%)
ABBV : 151.96 (+1.91%)
Should First Trust Value Line Dividend ETF (FVD) Be on Your Investing Radar?

Style Box ETF report for FVD

FVD : 40.37 (+0.37%)
CAT : 209.31 (+1.78%)
SRE : 166.74 (+0.38%)
LLY : 307.01 (+0.34%)
VTV : 141.09 (+0.69%)
IWD : 155.72 (+0.69%)
4 Large Drug Stocks to Watch as the Industry Recovers

Drug/biotech companies are likely to see significant advances in innovation in 2022. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and Glaxo (GSK) are worth...

LLY : 307.01 (+0.34%)
GSK : 44.97 (-0.07%)
NVO : 105.25 (-2.53%)
MRK : 93.75 (-0.94%)
AstraZeneca (AZN) Inks Deal to Develop COVID-19 Antibodies

AstraZeneca (AZN) partners with a U.K.-based biotech company to develop monoclonal antibodies targeting the COVID-causing virus.

AZN : 66.81 (+0.24%)
GSK : 44.97 (-0.07%)
LLY : 307.01 (+0.34%)
VIR : 23.66 (+3.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure...

See More

Key Turning Points

3rd Resistance Point 315.85
2nd Resistance Point 313.14
1st Resistance Point 310.07
Last Price 307.01
1st Support Level 304.29
2nd Support Level 301.58
3rd Support Level 298.51

See More

52-Week High 314.00
Last Price 307.01
Fibonacci 61.8% 268.73
Fibonacci 50% 254.75
Fibonacci 38.2% 240.77
52-Week Low 195.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar